AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15723979 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 652
Study 15723979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 11923041 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) stimulation
Number of subjects: 39
Study 11923041 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BV) stimulation
Number of subjects: 39
Study 11923041 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular (RV) stimulation
Number of subjects: 39
Study 11923041 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay optimization
Number of subjects: 39
Study 11923041 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter AV delay
Number of subjects: 39
Study 11923041 — intervention group
Group type: EXPERIMENTAL
Intervention: Responder subgroup
Number of subjects: 39
Study 11923041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponder subgroup
Number of subjects: 39
Study 9831693 — intervention group
Group type: EXPERIMENTAL
Intervention: d-aldosterone (12 pmol.min-1.kg-1)
Number of subjects: 14
Study 9831693 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (vehicle)
Number of subjects: 14
Study 8305384 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler velocimetry revealed to clinician (study group)
Number of subjects: 10
Study 8305384 — intervention group
Group type: COMPARATOR
Intervention: Doppler velocimetry not revealed to clinician (control group)
Number of subjects: 10
Study 2525328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 20 mg
Number of subjects: 8
Study 2525328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 40 mg
Number of subjects: 8
Study 2525328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil 60 mg
Number of subjects: 8
Study 2525328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2525328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 8
Study 30919004 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cue exposure in study 1
Number of subjects: 100
Study 30919004 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol priming (0.6 g/kg body weight) in study 2
Number of subjects: 100
Study 30919004 — intervention group
Group type: COMPARATOR
Intervention: Alcohol placebo beverage in study 2
Number of subjects: 100
Study 30919004 — intervention group
Group type: COMPARATOR
Intervention: Water in study 2
Number of subjects: 100
Study 28919097 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic j-pouch
Number of subjects: 74
Study 28919097 — intervention group
Group type: COMPARATOR
Intervention: Side-to-end anastomosis
Number of subjects: 74
Study 28919097 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (j-pouch and side-to-end anastomosis)
Number of subjects: 74
Study 26420334 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg Se-enriched yeast
Number of subjects: 491
Study 26420334 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg Se-enriched yeast
Number of subjects: 491
Study 26420334 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 μg Se-enriched yeast
Number of subjects: 491
Study 26420334 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo-yeast tablets
Number of subjects: 491
Study 24281461 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide, 1.5 to 2.5 mg/kg per day for 8 weeks
Number of subjects: 56
Study 24281461 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide for nonresponders to placebo
Number of subjects: 56
Study 24281461 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 56
Study 24281461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 22026481 — intervention group
Group type: EXPERIMENTAL
Intervention: FV-guided surgery
Number of subjects: 400
Study 22026481 — intervention group
Group type: COMPARATOR
Intervention: White light-guided surgery
Number of subjects: 400
Study 18709483 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d. for 8 weeks
Number of subjects: 40
Study 18709483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17168490 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynastat (new selective COX-2 inhibitor)
Number of subjects: 180
Study 17168490 — intervention group
Group type: COMPARATOR
Intervention: Profenid (conventional nonsteroidal anti-inflammatory drug)
Number of subjects: 180
Study 14531871 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragrance-containing solution (10 p.p.m. for 2 weeks, then 250 p.p.m. for 2 weeks)
Number of subjects: 15
Study 14531871 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 15
Study 14531871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fragrance-containing and placebo solutions
Number of subjects: 15
Study 11124551 — intervention group
Group type: EXPERIMENTAL
Intervention: J-pouch double tract reconstruction (PDT group)
Number of subjects: 40
Study 11124551 — intervention group
Group type: COMPARATOR
Intervention: rho-double tract reconstruction (RDT group)
Number of subjects: 40
Study 9124837 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/day for 3 days)
Number of subjects: 85
Study 9124837 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (40 mg/kg/day for 10 days)
Number of subjects: 85
Study 9124837 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 85
Study 9124837 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 85
Study 8235261 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761
Number of subjects: 165
Study 8235261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 3548368 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 0
Study 3548368 — intervention group
Group type: COMPARATOR
Intervention: Control (gel only)
Number of subjects: 0
Study 29515113 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide-based pseudosubstrates for cathepsin G
Number of subjects: 0
Study 29515113 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27577549 — intervention group
Group type: EXPERIMENTAL
Intervention: LHB tenotomy
Number of subjects: 98
Study 27577549 — intervention group
Group type: EXPERIMENTAL
Intervention: LHB tenodesis
Number of subjects: 98
Study 26324754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound training
Number of subjects: 150
Study 26324754 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical examination instruction
Number of subjects: 150
Study 23041960 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% HRmax
Number of subjects: 10
Study 23041960 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% HRmax
Number of subjects: 10
Study 23041960 — intervention group
Group type: EXPERIMENTAL
Intervention: 85% HRmax
Number of subjects: 10
Study 22080777 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant Recess® intervention (10-minute PA breaks introduced in classrooms)
Number of subjects: 8
Study 22080777 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 8
Study 19169930 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of oxytocin until delivery
Number of subjects: 138
Study 19169930 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of oxytocin at the onset of the active phase
Number of subjects: 138
Study 16514097 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement therapy (CI therapy)
Number of subjects: 0
Study 16514097 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (physical fitness, cognitive, and relaxation exercises)
Number of subjects: 0
Study 12721259 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide 500 mg/m2 day 1, doxorubicin 40 mg/m2 day 1, and fluorouracil 200 mg/m2 intravenous bolus days 1 to 5)
Number of subjects: 242
Study 12721259 — intervention group
Group type: COMPARATOR
Intervention: CAF plus LV (leucovorin 200 mg/m2 over 30 minutes days 1 to 5 given 1 hour before FU)
Number of subjects: 242
Study 12721259 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 242
Study 12721259 — intervention group
Group type: COMPARATOR
Intervention: CAF plus LV
Number of subjects: 242
Study 11175474 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 441
Study 11175474 — intervention group
Group type: COMPARATOR
Intervention: Optimal PTCA
Number of subjects: 441
Study 11175474 — intervention group
Group type: COMPARATOR
Intervention: Non-optimal PTCA
Number of subjects: 441
Study 9404405 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (L-arg, 625 mg/min x 10 min)
Number of subjects: 15
Study 9404405 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFX, 50 mg/min x 10 min)
Number of subjects: 15
Study 9404405 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary isosorbide dinitrate
Number of subjects: 15
Study 8371658 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of a 5% rice‐based liquid (L‐CHO)
Number of subjects: 6
Study 8371658 — intervention group
Group type: EXPERIMENTAL
Intervention: 31-g food bar (S‐CHO)
Number of subjects: 6
Study 8371658 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (both L-CHO and S-CHO)
Number of subjects: 6
Study 8371658 — intervention group
Group type: COMPARATOR
Intervention: 500 ml of sweet placebo (CON)
Number of subjects: 6
Study 2876574 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1 (single dose)
Number of subjects: 0
Study 2876574 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.015 mg kg‐1 followed by 0.085 mg kg‐1 (divided doses)
Number of subjects: 0
Study 2876574 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1 (single dose)
Number of subjects: 0
Study 2876574 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.075 mg kg‐1 followed by 0.425 mg kg‐1 (divided doses)
Number of subjects: 0
Study 2876574 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming at 6 min
Number of subjects: 0
Study 2876574 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming (general)
Number of subjects: 0
Study 2876574 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant awareness of muscle weakness
Number of subjects: 0
Study 30381400 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Denosumab (DNM) subcutaneously on day 0 and 180
Number of subjects: 63
Study 30381400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 30381400 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Denosumab (DNM)
Number of subjects: 63
Study 27310955 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight mesh (LWM)
Number of subjects: 61
Study 27310955 — intervention group
Group type: COMPARATOR
Intervention: Heavyweight mesh (HWM)
Number of subjects: 61
Study 25417309 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D3
Number of subjects: 44
Study 25417309 — intervention group
Group type: COMPARATOR
Intervention: Control (no 1,25-dihydroxyvitamin D3)
Number of subjects: 44
Study 23187888 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose of zidovudine (100 μg)
Number of subjects: 0
Study 23187888 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose of tenofovir (100 μg)
Number of subjects: 0
Study 23187888 — intervention group
Group type: COMPARATOR
Intervention: Standard unlabelled dose of zidovudine (300 mg)
Number of subjects: 0
Study 23187888 — intervention group
Group type: COMPARATOR
Intervention: Standard unlabelled dose of tenofovir (300 mg)
Number of subjects: 0
Study 19834350 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-long exercise condition
Number of subjects: 104
Study 19834350 — intervention group
Group type: COMPARATOR
Intervention: Control exercise condition
Number of subjects: 104
Study 19834350 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise conditions
Number of subjects: 104
Study 18690118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine cigarette (0.6 mg)
Number of subjects: 72
Study 18690118 — intervention group
Group type: EXPERIMENTAL
Intervention: Denicotinized cigarette (0.05 mg)
Number of subjects: 72
Study 15842665 — intervention group
Group type: EXPERIMENTAL
Intervention: HiDAC 1 group (ASCT immediately after one course of HiDAC)
Number of subjects: 128
Study 15842665 — intervention group
Group type: COMPARATOR
Intervention: HiDAC 2 group (ASCT after one more course of HiDAC)
Number of subjects: 128
Study 12705643 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (Group II)
Number of subjects: 41
Study 12705643 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG (Group I)
Number of subjects: 41
Study 10028138 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-state mixed renewal process model for chronic disease activity
Number of subjects: 0
Study 10028138 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified analyses based on the number of past exacerbations
Number of subjects: 0
Study 8911222 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term tryptophan depletion (24-hour low-tryptophan diet followed by an amino acid drink)
Number of subjects: 20
Study 8911222 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion (placebo)
Number of subjects: 20
Study 1589157 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 145
Study 1589157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 3922639 — intervention group
Group type: EXPERIMENTAL
Intervention: HAC (Hexamethylmelamine, adriamycin, and cyclophosphamide)
Number of subjects: 120
Study 3922639 — intervention group
Group type: COMPARATOR
Intervention: PAC (cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide)
Number of subjects: 120
Study 3922639 — intervention group
Group type: EXPERIMENTAL
Intervention: HAC
Number of subjects: 120
Study 3922639 — intervention group
Group type: COMPARATOR
Intervention: PAC
Number of subjects: 120
Study 3922639 — intervention group
Group type: EXPERIMENTAL
Intervention: HAC and PAC
Number of subjects: 120
Study 30427948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, 1 μg/kg over 10 min
Number of subjects: 30
Study 30427948 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-jaundiced patients)
Number of subjects: 30
Study 27119439 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 0
Study 24677163 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived discrimination
Number of subjects: 1056
Study 24677163 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 1056
Study 24677163 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 1056
Study 24677163 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived discrimination with stress and depression included
Number of subjects: 1056
Study 22313605 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to fictitious peer's food choices (familiar or unfamiliar)
Number of subjects: 316
Study 22313605 — intervention group
Group type: EXPERIMENTAL
Intervention: Fictitious peer influence
Number of subjects: 316
Study 22313605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention programmes using peer influence
Number of subjects: 316
Study 20643014 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral thigh flap
Number of subjects: 19
Study 20643014 — intervention group
Group type: COMPARATOR
Intervention: Radial forearm free flap
Number of subjects: 19
Study 18603344 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised dentures (intervention)
Number of subjects: 47
Study 16039333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 510
Study 16039333 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 510
Study 12442929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine papaverine (30 mg)
Number of subjects: 66
Study 12442929 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.375% 30 mL)
Number of subjects: 66
Study 12442929 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (30 mL)
Number of subjects: 66
Study 11382889 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation during sleep
Number of subjects: 84
Study 11382889 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental nights with auditory arousal threshold studies
Number of subjects: 84
Study 11382889 — intervention group
Group type: COMPARATOR
Intervention: Clinical groups vs. respective controls
Number of subjects: 84
Study 8955676 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-123-iodobenzamide (185 MBq, 5 mCi)
Number of subjects: 20
Study 8955676 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 20
Study 1657017 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (75 mg orally)
Number of subjects: 6
Study 6360349 — intervention group
Group type: EXPERIMENTAL
Intervention: vincristine (1.4 mg/m2)
Number of subjects: 63
Study 6360349 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine (3 mg/m2)
Number of subjects: 63
Study 30769214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% 20 mL
Number of subjects: 60
Study 30769214 — intervention group
Group type: COMPARATOR
Intervention: Placebo 20 mL
Number of subjects: 60
Study 30149088 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained CPR Coach
Number of subjects: 200
Study 27060362 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 135
Study 27060362 — intervention group
Group type: COMPARATOR
Intervention: Epoetin beta
Number of subjects: 135
Study 24112799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 33
Study 24112799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 23094720 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 294
Study 23094720 — intervention group
Group type: COMPARATOR
Intervention: Class IC or class III antiarrhythmic agents
Number of subjects: 294
Study 18832432 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg citalopram (CIT)
Number of subjects: 14
Study 18832432 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 14
Study 17095239 — intervention group
Group type: EXPERIMENTAL
Intervention: 10ml 0.5% bupivicaine injected to the port sites before incision
Number of subjects: 31
Study 17095239 — intervention group
Group type: COMPARATOR
Intervention: 10ml saline
Number of subjects: 31
Study 15702439 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma leptin measurement in patients with SAD
Number of subjects: 35
Study 15702439 — intervention group
Group type: COMPARATOR
Intervention: Plasma leptin measurement in matched controls
Number of subjects: 35
Study 15702439 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of depression severity, appetite scores, and BMI in patients with SAD
Number of subjects: 35
Study 15702439 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of body weight changes in subjects with SAD
Number of subjects: 35
Study 12214580 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate dihydrate (Oxis) at doses of 4.5, 18, and 54 microg via Turbuhaler
Number of subjects: 28
Study 12214580 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol at doses of 200 and 1800 microg via pressurised metered dose inhaler (pMDI)
Number of subjects: 28
Study 12214580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9862585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium hydroxide (4.5 g per g elemental iron ingested)
Number of subjects: 13
Study 9862585 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 13
Study 7657902 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Guidelines Nutrition Care (PGC)
Number of subjects: 179
Study 7657902 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Nutrition Care (BC)
Number of subjects: 179
Study 7657902 — intervention group
Group type: COMPARATOR
Intervention: Non-random comparison group (no dietitian contact)
Number of subjects: 179
Study 2611358 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (CT; combination of sulphamethoxazole 800 mg and trimethoprim 160 mg, twice daily for 5 days)
Number of subjects: 8
Study 2611358 — intervention group
Group type: COMPARATOR
Intervention: Control (TH alone)
Number of subjects: 8
Study 976306 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutiorex 20 mg orally
Number of subjects: 10
Study 976306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31673330 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM plus physical treatments
Number of subjects: 108
Study 31673330 — intervention group
Group type: COMPARATOR
Intervention: Physical treatments alone
Number of subjects: 108
Study 29182076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29182076 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 26597311 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50% (6.5mg) DHEA daily for 12 weeks
Number of subjects: 482
Study 26597311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study 23636069 — intervention group
Group type: EXPERIMENTAL
Intervention: Early screening with the Gugging Swallowing Screen and intensified oral hygiene
Number of subjects: 146
Study 23636069 — intervention group
Group type: COMPARATOR
Intervention: Internal control group (retrospectively selected from same clinic)
Number of subjects: 146
Study 23636069 — intervention group
Group type: COMPARATOR
Intervention: External control group (from a comparable stroke unit in a neighboring hospital)
Number of subjects: 146
Study 21785156 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised action plan (AP)
Number of subjects: 233
Study 21785156 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 233
Study 19378685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 166
Study 19378685 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare metal stent
Number of subjects: 166